Tags · Compound
tirzepatide
Dual GIP and GLP-1 receptor agonist.
Related in this group: semaglutide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues
73 topics · page 2 of 3
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version
On the subject in the title: Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long version Working notes rather than a conclusion. A narrow question about Tirzepatide in type 2…
|
+85 | 90 | 13k | 7mo |
|
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+18 | 29 | 20k | 8mo |
|
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. Reading back through what has been written here about…
|
+4 | 8 | 14k | 8mo |
|
[2026 update] What steady state means for the decision to escalate
The question in the title: What steady state means for the decision to escalate I will give what I have already checked below so nobody repeats it. Asking about steady state directly, because I have read four…
|
+127 | 137 | 32k | 8mo |
|
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here…
|
+89 | 101 | 32k | 8mo |
|
Follow-up: The lowest dose that does anything: is that a real question?
The question in the title: The lowest dose that does anything: is that a real question? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still…
|
+70 | 75 | 12k | 8mo |
|
Revisiting: GLP-1 receptor distribution: central and peripheral
Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. An honest uncertainty about GLP-1 receptor distribution rather than a…
|
+61 | 66 | 15k | 8mo |
|
Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Asking directly, because I could not find a straight answer: Tirzepatide and nausea: is the profile genuinely different or just differently reported? Asking about tirzepatide and nausea directly, because I…
|
+18 | 22 | 37k | 8mo |
|
About the Pharmacokinetics category
Half-life, accumulation, steady state, albumin binding, and why weekly dosing works. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 32k | 8mo | |
|
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A follow-up question about appetite effects that I did not know to ask the first time. The earlier thread…
|
+86 | 90 | 61k | 9mo |
|
Amylin receptor signalling and satiety
Amylin receptor signalling and satiety Writing it up because I had to work it out twice and would rather nobody else did. Asking about amylin receptor signalling and satiety directly, because I have read four…
|
+22 | 26 | 1.8k | 9mo |
|
Dose numbers across compounds are not on the same scale
Dose numbers across compounds are not on the same scale — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on dose numbers across…
|
2 | 1.6k | 9mo | |
|
How the published trials escalated, tabulated side by side — does this still hold?
Asking directly, because I could not find a straight answer: How the published trials escalated, tabulated side by side — does this still hold? Asking about published trials escalated directly, because I have…
|
2 | 8.9k | 9mo | |
|
SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on
Posting this under the heading it deserves: SURMOUNT-4 and what withdrawal data does and does not tell an individual — one year on Everything below is what sits behind that. I would like to disagree carefully…
|
+122 | 136 | 48k | 9mo |
|
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept I have read the maintained page on this and I still have a gap, so I…
|
+7 | 11 | 26k | 9mo |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version
Asking directly, because I could not find a straight answer: What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version A narrow question about GIP…
|
+48 | 52 | 609 | 10mo |
|
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. A question about GIP receptor agonism that I think has a definite answer, unlike…
|
2 | 867 | 10mo | |
|
Escalating every six weeks instead of four: what I observed over eight months — one year on
On the subject in the title: Escalating every six weeks instead of four: what I observed over eight months — one year on Working notes rather than a conclusion. Asking about Escalating every six weeks instead…
|
+55 | 59 | 9.1k | 10mo |
|
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
|
+35 | 39 | 547 | 11mo |
|
SURMOUNT-4 and what withdrawal data does and does not tell an individual
SURMOUNT-4 and what withdrawal data does and does not tell an individual — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on…
|
4 | 42k | 11mo | |
|
Vagal afferents and the gut-brain pathway — one year on
Vagal afferents and the gut-brain pathway — one year on Writing it up because I had to work it out twice and would rather nobody else did. An honest uncertainty about Vagal afferents rather than a disguised…
|
2 | 136 | 11mo | |
|
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. Reading back through what has been written here about Tirzepatide in…
|
2 | 58k | 11mo | |
|
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
|
+150 | 163 | 22k | 11mo |
|
Titrating on tolerability rather than on the calendar
On the subject in the title: Titrating on tolerability rather than on the calendar Working notes rather than a conclusion. An honest uncertainty about titrating on tolerability rather than a disguised…
|
2 | 31k | 13mo | |
|
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. Vagal afferents — I have the observation and I do not trust my interpretation of it, so I am…
|
+5 | 9 | 44k | 13mo |
|
About the Tirzepatide category
Dual GIP/GLP-1 receptor agonist. SURPASS and SURMOUNT programme data, titration, and comparative discussion. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
+2 | 6 | 132 | 13mo |
|
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the kinetics rather than the pharmacology, because I…
|
+115 | 130 | 44k | 13mo |
|
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. A narrow question about albumin binding, deliberately narrow, because the broad…
|
+38 | 44 | 6.6k | 14mo |
|
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
|
2 | 763 | 15mo | |
|
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Appetite effects: what I expected, what I found, and the gap between them. I…
|
2 | 56k | 16mo |